On March 17, 2022, the Board of Directors (the Board) of Emergent BioSolutions Inc. (the Company) appointed Keith Katkin as a Class I director of the Company, effective as of April 1, 2022 (the Effective Date), with an initial term expiring at the 2022 annual meeting of stockholders. He was also appointed as a member of both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board, as of the Effective Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.55 USD | +5.31% | +27.59% | +131.25% |
05-02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
05-02 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+131.25% | 291M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Appoints Keith Katkin as a Class I Director, Member of Both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board